Prediction of 18F-FES-PET/CT Parameters on Palbociclib Combined With ET
To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.
Metastatic Breast Cancer
DRUG: Palbociclib
PFS, Through study completion, an expected average of 12 months
To investigate parameters based on 18F-FES-PET/CT so as to estimate the outcome of palbociclib combined with endocrine therapy in patients with HR+/HER2-MBC.